← Leaderboards
E Premkumar Reddy
Temple University
$22,814,761
Attributed
$22,814,761
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,814,761 · 16
By mechanism
R01$13,150,383 · 9
P01$7,406,147 · 3
R24$1,252,455 · 1
R21$824,663 · 2
T32$181,113 · 1
Top collaborators
No co-investigators on record.
Most similar at Temple University
Same institution · by research overlap
- Xavier Grana$5,217,972
- Bassel E Sawaya$12,573,780
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellKinase InhibitorTumorCell CycleBiological ModelsCellsGrowthMolecularMalignant NeoplasmsCell ProliferationCessation Of LifeCell DeathResistanceSmall MoleculeOncogenesPathway InteractionsBaseClinical TrialsPharmaceutical PreparationsIn VitroProteinsGenesLaboratory MouseExhibits
Grant awards (60)
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia$498,956
R01 · FY2024 · CA · contact PI
Targeting FL3 and SRC kinases for AML therapy$187,642
R21 · FY2024 · CA · contact PI
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia$514,712
R01 · FY2023 · CA · contact PI
Targeting FL3 and SRC kinases for AML therapy$237,023
R21 · FY2023 · CA · contact PI
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia$514,712
R01 · FY2022 · CA · contact PI
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia$525,216
R01 · FY2021 · CA · contact PI
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia$525,216
R01 · FY2020 · CA · contact PI
Utility of RAS mimetics to block oncogenic signaling in colorectal cancer$178,800
R21 · FY2019 · CA · contact PI
Utility of RAS mimetics to block oncogenic signaling in colorectal cancer$221,198
R21 · FY2018 · CA · contact PI
Targeting Mitotic Kinases Inhibitors for Cancer Therapy$351,713
R01 · FY2016 · CA · contact PI
Targeting Mitotic Kinases Inhibitors for Cancer Therapy$351,713
R01 · FY2015 · CA · contact PI
Targeting Mitotic Kinases Inhibitors for Cancer Therapy$341,162
R01 · FY2014 · CA · contact PI
Targeting Mitotic Kinases Inhibitors for Cancer Therapy$330,610
R01 · FY2013 · CA · contact PI
Targeting CDK4 in TGS-B Inactivated Gastrointestinal Cancers$170,834
P01 · FY2013 · CA · contact PI
Targeting Mitotic Kinases Inhibitors for Cancer Therapy$351,713
R01 · FY2012 · CA · contact PI
Targeting CDK4 in TGF-B Inactivated Gastrointestinal Cancers$274,209
P01 · FY2012 · CA · contact PI
Role of C-myb in Hematopoiesis and Cancer$423,750
R01 · FY2010 · HL · contact PI
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM$347,873
R01 · FY2010 · HL · contact PI
Targeting CDK4 in TGF-B Inactivated Gastrointestinal Cancers$292,790
P01 · FY2010 · CA · contact PI
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM$7,694
R01 · FY2010 · HL · contact PI
Role of C-myb in Hematopoiesis and Cancer$375,000
R01 · FY2009 · HL · contact PI
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM$355,568
R01 · FY2009 · HL · contact PI
Targeting CDK4 in TGF-B Inactivated Gastrointestinal Cancers$305,683
P01 · FY2009 · CA · contact PI
Role of C-myb in Hematopoiesis and Cancer$375,000
R01 · FY2008 · HL · contact PI
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM$355,568
R01 · FY2008 · HL · contact PI
Targeting Cell Cycle Machinery For Cancer Therapy$269,680
R01 · FY2008 · CA · contact PI
Targeting CDK4 in TGF-B Inactivated Gastrointestinal Cancers$213,618
P01 · FY2008 · CA · contact PI
Targeting Cell Cycle Machinery For Cancer Therapy$22,858
R01 · FY2008 · CA · contact PI
G1 Cell Cycle in Tumorigenesis and Senescence$1,267,414
P01 · FY2007 · CA · contact PI
Role of C-myb in Hematopoiesis and Cancer$375,000
R01 · FY2007 · HL · contact PI
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM$355,568
R01 · FY2007 · HL · contact PI
Targeting Cell Cycle Machinery For Cancer Therapy$292,538
R01 · FY2007 · CA · contact PI
G1 Cell Cycle in Tumorigenesis and Senescence$1,270,526
P01 · FY2006 · CA · contact PI
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM$375,000
R01 · FY2006 · HL · contact PI
Role of CDK4 in Cell Cycle Progression and Cancer$367,408
R01 · FY2006 · AG · contact PI
Targeting Cell Cycle Machinery For Cancer Therapy$301,275
R01 · FY2006 · CA · contact PI
G1 Cell Cycle in Tumorigenesis and Senescence$1,246,379
P01 · FY2005 · CA
Role of CDK4 in Cell Cycle Progression and Cancer$376,250
R01 · FY2005 · AG
Targeting Cell Cycle Machinery For Cancer Therapy$308,525
R01 · FY2005 · CA
SHARED RESOURCES FOR CANCER RESEARCH$262,299
R24 · FY2005 · CA
G1 Cell Cycle in Tumorigenesis and Senescence$1,175,346
P01 · FY2004 · CA
Role of CDK4 in Cell Cycle Progression and Cancer$376,250
R01 · FY2004 · AG
Targeting Cell Cycle Machinery For Cancer Therapy$308,525
R01 · FY2004 · CA
SHARED RESOURCES FOR CANCER RESEARCH$254,657
R24 · FY2004 · CA
G1 Cell Cycle in Tumorigenesis and Senescence$1,189,348
P01 · FY2003 · CA
Role of CDK4 in Cell Cycle Progression and Cancer$376,250
R01 · FY2003 · AG
MYB GENE FAMILY AND BREAST CANCER$308,344
R01 · FY2003 · CA
SHARED RESOURCES FOR CANCER RESEARCH$247,241
R24 · FY2003 · CA
Role of CDK4 in Cell Cycle Progression and Cancer$376,250
R01 · FY2002 · AG
MYB GENE FAMILY AND BREAST CANCER$300,597
R01 · FY2002 · CA
SHARED RESOURCES FOR CANCER RESEARCH$240,038
R24 · FY2002 · CA
AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE$225,103
R01 · FY2002 · ES
MYB GENE FAMILY AND BREAST CANCER$293,079
R01 · FY2001 · CA
SHARED RESOURCES FOR CANCER RESEARCH$248,220
R24 · FY2001 · CA
AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE$212,181
R01 · FY2001 · ES
AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE$50,000
R01 · FY2001 · ES
MYB GENE FAMILY AND BREAST CANCER$285,775
R01 · FY2000 · CA
JAK-3 AND MYELOID CELL DIFFERENTIATION$235,570
R01 · FY2000 · CA
AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASE$212,181
R01 · FY2000 · ES
TRAINING IN CANCER AND CANCER RELATED RESEARCH$181,113
T32 · FY2000 · CA